Table 2.
Prevalence of SARS-CoV-2 antibodies by test type and by primary and secondary seroprevalence measures, among pregnant women in Johannesburg, South Africa, March-June 2021.
| SARS-CoV-2 Seropositivity |
|||||
|---|---|---|---|---|---|
| N | Wantai assay n (%N) | Roche assay n (%N) | Primary: EITHER Wantai or Roche Assay n (%N) | Secondary: BOTH Wantai AND Roche Assay n (%N) | |
| Overall | 500 | 298 (59.6) | 292 (58.4) | 320 (64.0) | 270 (54.0) |
| 95% confidence interval |
55.2-63.9 | 53.9-62.8 | 59.6-68.2 | 49.5-58.4 | |
| HIV status | |||||
| Positive | 131 | 73 (55.7) | 64 (48.9) | 76 (58.0) | 61 (46.6) |
| Negative | 360 | 220 (61.1) | 222 (61.7) | 238 (66.1) | 204 (56.7) |
| Unknown | 4 | 4 (100.0) | 4 (100.0) | 4 (100.0) | 4 (100.0) |
| P-value | 0.298 | 0.018 | 0.117 | 0.178 | |
| HIV viral load (copies/ml)a | |||||
| <100 | 69 | 35 (50.7) | 33 (47.8) | 36 (52.2) | 32 (46.4) |
| ≥100 | 12 | 6 (50.0) | 6 (50.0) | 7 (58.3) | 5 (41.7) |
| P-value | 0.963 | 0.888 | 0.681 | 0.824 | |
| CD4+ T cells (count/ml)a | |||||
| ≥350 | 39 | 23 (58.9) | 22 (56.4) | 24 (61.5) | 21 (53.9) |
| <350 | 18 | 7 (38.9) | 4 (22.2) | 7 (38.9) | 4 (22.2) |
| P-value | 0.203 | 0.046 | 0.157 | 0.105 | |
a
Of the 131 women living with HIV, viral load results were only available for 81 (62%) participants and CD4 results were available for 57 (44%) participants, up to 3 months prior to study participation.
CD, clusters of differentiation